According to a post hoc analysis of the SCORED study, the use of Inpefa was shown to reduce the risk of total cardiovascular (CV) deaths, hospitalisations, or urgent visits by 29% compared to placebo.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,